Report ID: SQMIG35A2816
Report ID:
SQMIG35A2816 |
Region:
Global |
Published Date: July, 2024
Pages:
219
|
Tables:
95 |
Figures:
76
Global Growth Hormone Deficiency Market size was valued at USD 3.47 billion in 2022 and is poised to grow from USD 3.70 billion in 2023 to USD 6.12 billion by 2031, growing at a CAGR of 6.50% in the forecast period (2024-2031).
The escalating prevalence of growth hormone deficiency (GHD), attributed to various factors such as brain injuries, genetic disorders, congenital conditions, and certain medical treatments, has spurred a heightened demand for growth hormone therapies. According to the National Center for Biotechnology Information (NCBI), pediatric growth hormone deficiency is identified in approximately 1 in every 3,500–4,000 children in the United Kingdom. This growing incidence has propelled the expansion of the industry, with increased research and development activities playing a pivotal role. Notably, in February 2022, a significant milestone was achieved as Pfizer and OPKO secured marketing authorization from the European Union for their Once-Weekly NGENLA™ (somatrogon) Injection.
Our industry expert will work with you to provide you with customized data in a short amount of time.
REQUEST FREE CUSTOMIZATIONWant to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Report ID: SQMIG35A2816